The class of weight-loss drugs called GLP-1a – better known to most people as Ozempic and Wegovy – has been the focus of massive media attention since 2023. Countless claims have been made by food consultants all over the world that the arrival of GLP-1a is a transformational and disruptive moment.

These claims are unsettling for industry executives, many of whom are wondering how to respond. But fear not! Our latest strategy briefing has been written with these exact concerns in mind. It sets out what the industry’s responses could be to this supposed threat, explains why there is no need for panic, and the many opportunities that it presents.

Some of the many things you can expect to learn from the report:

- Why existing consumer trends are more powerful than the GLP-1 effect

- The four consumer segments that food companies need to bear in mind when thinking about how to respond

- Why GLP-1 usage is niche, and likely to stay that way

- The three key needs for GLP-1 users

- The five biggest category & ingredient opportunities

- What categories are at the biggest risk, and why that risk may not be as big as some would have you think

- The many limitations of GLP-1 drugs, and why the balance of probabilities leans to disappointment for these drugs in long-term weight loss

Get your copy of the report here: https://www.new-nutrition.com/nnbReport/display/371